Objective: To study the effect of cystatin C on the development of cognitive disorders(CD) in patients with CKD(Chronic kidney disease) and vascular parkinsonism

Background: Clinical and neurological features of the course of Parkinsonism disease in patients with CKD (Chronic kidney disease) is an urgent problem of medicine

Method: 210 patients with CKD in terminal stage were studied. The average age of all patients was 46.2±15.01 years. All patients were assessed for cognitive status using the SAGE scale as well as serum levels of cystatin C

Results: Out of the total number of patients, vascular parkinsonism developed in 54 (25.7%) patients. The average age of patients with advanced joint venture was 37±11.5. The duration of CKD at the time of diagnosis was 5.7±2.4 (4-7). According to the results of the SAGE scale, in the study of cognitive status, 18 (33.3%) patients had mild CD, 24 (44.4%) had moderate cognitive disorders, and 8 (14.8%) had dementia disorders.  When studying the levels of cystatin C, in patients with mild CD, its level was 4.4±0.75 (p=0.001); in patients with moderate CD 6.1±1.2 (p=0.001); in patients with dementia disorders 8.9±1.7 (p=0.05). A statistically significant relationship was also revealed between the level of cystatin and the indicators of the SAGE scale, which is equal to (r =-0.77***, P<0.001). Regression analysis of the data also revealed the potential effect of cystatin C on the development of CD (p <0.003) (R2=0.33; F=41.09; p <0.001).

Conclusion: In patients with CKD with advanced vascular Parkinsonism, CD are detected, the severity of which depends on the level of Cystatin

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/clinical-and-neurological-features-of-the-course-of-parkinsonism-disease-in-patients-with-ckd-with-cystatin-c-disorder/